Work Here?
About Ceribell
Industries
Healthcare
Company Size
201-500
Company Stage
Series C
Total Funding
$146.9M
Headquarters
Mountain View, California
Founded
2014
Overview
Ceribell focuses on developing medical devices that utilize electroencephalogram (EEG) technology to monitor brain activity. Their main product, the Ceribell EEG Headband and Recorder, is designed for use by trained healthcare providers in professional settings. These devices help gather important data about a patient's brain activity, which healthcare professionals can analyze to make informed treatment decisions, especially in urgent situations like Nonconvulsive Status Epilepticus (NCSE). Unlike some other EEG devices, Ceribell's products do not provide diagnostic conclusions or automated alerts; they are purely tools for data collection. Ceribell differentiates itself by emphasizing the speed and efficiency of data gathering, which is crucial in time-sensitive medical scenarios. The company's goal is to enhance the ability of healthcare providers to diagnose and treat neurological conditions effectively.
Simplify's Take
What believers are saying
- AI integration enhances Ceribell's diagnostic capabilities, providing a competitive market edge.
- Growing EEG market demand due to rising neurological disorders benefits Ceribell's product sales.
- Point-of-care testing trend supports adoption of Ceribell's portable EEG system.
What critics are saying
- Emerging AI-powered EEG technologies increase competition, threatening Ceribell's market share.
- Regulatory scrutiny on AI medical devices could lead to compliance costs and delays.
- Scaling production post-IPO may cause supply chain bottlenecks, affecting delivery timelines.
What makes Ceribell unique
- Ceribell's EEG system is FDA cleared and requires no specialist interpreter.
- The Brain Stethoscope function converts brainwaves to sound for easy seizure detection.
- Ceribell's EEG system can be set up in 6 minutes by any healthcare provider.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$146.9M
Above
Industry Average
Funded Over
4 Rounds
Industry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Unlimited Paid Time Off
Paid Holidays
Parental Leave
Annual Bonus Opportunity
Company Equity
Phone/Internet Stipend
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↑ 0%—Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions (“Ceribell”), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. “Ms
Ceribell, a former Fierce Medtech Fierce 15 honoree, has been developing a point-of-care electroencephalography platform that combines a disposable, brain-reading headset with artificial intelligence-powered algorithms that help detect hidden seizures-also known as electrographic status epilepticus, or ESE.
CeriBell, a medical device maker with an EEG platform that uses AI to monitor patient seizures, announced terms for its IPO on Monday.
Healthcare sales veteran to lead sales strategies and initiatives to propel continued commercial growthSUNNYVALE, Calif., April 2, 2024 /PRNewswire/ -- Today, Ceribell, Inc.®, the developer of the first AI-powered point-of-care EEG diagnostic system, announced the appointment of Sean Manni as Senior Vice President of Sales. In this role, Mr. Manni will lead Ceribell's commercial sales organization as it continues to expand its U.S. footprint."Sean brings an impressive blend of accomplishments, strategy, and leadership that will undoubtedly elevate our entire commercial organization," said Ceribell co-founder and CEO Jane Chao, Ph.D. "His guidance will be instrumental in developing and executing our plans to further expand our market presence in the U.S., ultimately benefiting patients by increasing access to our groundbreaking technology.""Joining Ceribell represents a unique opportunity to collaborate with an exceptional leadership and sales team," said Manni. "I am deeply committed to leveraging my experience in healthcare sales to further innovate Ceribell's sales strategies and ensure our revolutionary AI-powered point-of-care EEG solutions reach patients in need."Mr
SUNNYVALE, Calif., Jan. 4, 2024 /PRNewswire/ -- Ceribell, Inc.®, the developer of the first AI-powered point-of-care EEG system, announced today that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 8, 2024, at 8:00 a.m. Pacific Standard Time.Event: 42nd Annual J.P. Morgan Healthcare ConferenceDate: Monday, January 8, 2024Time: 8:00 a.m
Ceribell is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Ceribell
Industries
Healthcare
Company Size
201-500
Company Stage
Series C
Total Funding
$146.9M
Headquarters
Mountain View, California
Founded
2014
Ceribell is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today